Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests may predict sepsis death risk

NCT ID NCT07521306

Knowledge-focused Sponsor: Antalya Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examined whether routine blood tests (like PCT, CRP, and lactate) can help predict the risk of death within 28 days in adults admitted to the ICU with suspected sepsis. Researchers reviewed medical records of 250 patients to find links between these biomarkers and survival. The goal was to improve early identification of high-risk patients, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

250 people

The number who actually took part.

Started

May 2023

Finished

Aug 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is patients older than 18 years of age who have primary diagnoses of admission to intensive care unit are infection and suspected sepsis.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \>18 years of age * admission to the ICU with suspected sepsis Exclusion Criteria: * ICU admission following cardiopulmonary resuscitation or cardiac surgery * Having a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection * Interruption of the treatment process because of transfer to another healthcare facility

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarkers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarkers Mortality Sepsis

Contacts and locations

Locations

  • Niğde Ömer Halisdemir University Training and Research Hospital

    Niğde, Niğde Province, 51200, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.